Citations

Mayo Clinic

Showing 10 of 108599 citations.

Meeting Report: 11th and 12th Annual Meetings of the Society of Anesthesia and Sleep Medicine: Taking Sleep Health Into the Next Decade
Pappu, Ameya , Ramachandran, Satya Krishna , Auckley, Dennis , Won, Christine , Gali, Bhargavi , Hargett, Mary J. , Nafiu, Olubukola O. , Dominguez, Jennifer E. , Singh, Mandeep

Anesthesia & Analgesia | September 21, 2023 | Volume: 137 | Issue: 6 | Pages: e45-e48

10.1213/ane.0000000000006632 | PMID 40009003 Get It

Germline Sequencing Analysis to Inform Clinical Gene Panel Testing for Aggressive Prostate Cancer
Saunders, Edward J. , Sheng, Xin , Wan, Peggy , Pooler, Loreall , Xia, Lucy , Chanock, Stephen, Berndt, Sonja I., Patel, Alpa V. , Albanes, Demetrius, Weinstein, Stephanie J. , Gnanapragasam, Vincent J. , Huff, Chad D. , Pomerantz, Mark M., Schmidt, Julie A. , Travis, Ruth C. , Mucci, Lorelei A. , Catàlona, William J. , Marosy, Beth, Hetrick, Kurt N. , Doheny, Kimberly F. , MacInnis, Robert J. , Eeles, Rosalind A. , Kote‐Jarai, Zsofia , Haiman, Christopher A. , Eeles, Rosalind A , Travis, Ruth C , Maclnnis, Robert , Darst, Burcu F. , Dadaev, Tokhir , Berndt, Sonja I. , Wang, Ying , Couch, Fergus J. , Wolk, Alicja , Giles, Graham G. , Nguyen‐Dumont, Tú , Milne, Roger L. , Key, Tim , Stopsack, Konrad H. , Southey, Melissa C. , Wiklund, Fredrik E. , Conti, David V.

JAMA Oncology | September 21, 2023 | Volume: 9 | Issue: 11 | Pages: 1514

10.1001/jamaoncol.2023.3482 | PMID 37733366 Get It

Importance Germline gene panel testing is recommended for men with advanced prostate cancer (PCa) or a family history of cancer. While evidence is limited for some genes currently included in panel testing, gene panels are also likely to be incomplete and missing genes that influence PCa risk and aggressive disease. Objective To identify genes associated with aggressive PCa. Design, Setting, and Participants A 2-stage exome sequencing case-only genetic association study was conducted including men of European ancestry from 18 international studies. Data analysis was performed from January 2021 to March 2023. Participants were 9185 men with aggressive PCa (including 6033 who died of PCa and 2397 with confirmed metastasis) and 8361 men with nonaggressive PCa. Exposure Sequencing data were evaluated exome-wide and in a focused investigation of 29 DNA repair pathway and cancer susceptibility genes, many of which are included on gene panels. Main Outcomes and Measures The primary study outcomes were aggressive (category T4 or both T3 and Gleason score ≥8 tumors, metastatic PCa, or PCa death) vs nonaggressive PCa (category T1 or T2 and Gleason score ≤6 tumors without known recurrence), and metastatic vs nonaggressive PCa. Results A total of 17 546 men of European ancestry were included in the analyses; mean (SD) age at diagnosis was 65.1 (9.2) years in patients with aggressive PCa and 63.7 (8.0) years in those with nonaggressive disease. The strongest evidence of association with aggressive or metastatic PCa was noted for rare deleterious variants in known PCa risk genes BRCA2 and ATM ( P ≤ 1.9 × 10 −6 ), followed by NBN ( P = 1.7 × 10 −4 ). This study found nominal evidence ( P < .05) of association with rare deleterious variants in MSH2 , XRCC2 , and MRE11A . Five other genes had evidence of greater risk (OR≥2) but carrier frequency differences between aggressive and nonaggressive PCa were not statistically significant: TP53 , RAD51D , BARD1 , GEN1 , and SLX4 . Deleterious variants in these 11 candidate genes were carried by 2.3% of patients with nonaggressive, 5.6% with aggressive, and 7.0% with metastatic PCa. Conclusions and Relevance The findings of this study provide further support for DNA repair and cancer susceptibility genes to better inform disease management in men with PCa and for extending testing to men with nonaggressive disease, as men carrying deleterious alleles in these genes are likely to develop more advanced disease.
A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis
Rinella, Mary E. , Lieu, Hsiao D., Goodman, Zachary , Alkhouri, Naim , Abdelmalek, Manal F. , Wong, Vincent Wai‐Sun , Younes, Ziad , Sheikh, Aasim , Brannan, Donald, Freilich, B., Membreno, Fernando E., Sinclair, Marie , Melchor‐Khan, Liza, Ling, Lei , Abdelmalek, Manal , Wong, Vincent Wai-Sun , Rinella, Mary , Kowdley, Kris V. , Lawitz, Eric , Ratziu, Vlad , Brannan, Donald, Sanyal, Arun J. , Harrison, Stephen A.

Hepatology | September 21, 2023 | Volume: 79 | Issue: 3 | Pages: 674-689

10.1097/hep.0000000000000607 | PMID 37732990 Get It

Background and Aims: Aldafermin, an engineered analog of the human hormone FGF19, improves liver histology in patients with noncirrhotic NASH; however, its efficacy and safety in compensated cirrhosis is unknown. No drug has yet to demonstrate benefit in the compensated NASH population. Approach and Results: In this multicenter, double-blind, placebo-controlled, phase 2b trial, 160 patients with compensated NASH cirrhosis were randomized to aldafermin 0.3 mg (n = 7), 1 mg (n = 42), 3 mg (n = 55), or placebo (n = 56) for 48 weeks. The 0.3 mg group was discontinued to limit exposure to suboptimal doses. The primary end point was a change in Enhanced Liver Fibrosis from baseline to week 48. The analyses were performed in the intention-to-treat population. At week 48, the least-squares mean difference in the change in Enhanced Liver Fibrosis was −0.5 (95% CI, −0.7 to −0.2; p = 0.0003) between the 3 mg group and the placebo group. 15%, 21%, and 23% of patients in the placebo, 1 mg, and 3 mg group, respectively, achieved fibrosis improvement ≥ 1 stage; and 13%, 16%, and 20% achieved fibrosis improvement ≥ 1 stage without NASH worsening. Improvement in alanine aminotransferase, aspartate aminotransferase, neoepitope-specific N-terminal pro-peptide of type III collagen, and liver stiffness favored aldefermin groups over placebo. Diarrhea was the most frequent adverse event, occurring at 26% and 40% in the 1 mg and 3 mg groups, respectively, compared to 18% in the placebo group. Overall, 0%, 2%, and 9% of patients in the placebo, 1 mg, and 3 mg group, respectively, discontinued due to treatment-related adverse events. Conclusions: Aldafermin 3 mg resulted in a significant reduction in Enhanced Liver Fibrosis in patients with compensated NASH cirrhosis.
Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?
Lemoinne, Sara , Soret, Pierre‐Antoine , Gulamhusein, Aliya , Lytvyak, Ellina , Olivas, Ignasi , Eaton, John E. , Sebode, Marcial , Lohse, Ansgar W. , Nevens, Frederik , Cazzagon, Nora , Zago, Alessandra , Russo, Francesco Paolo , Floreani, Annarosa , Abbas, Nadir , Thorburn, Douglas , Delamarre, Adèle , Sobenko, Natalia , Villamil, Alejandra , Patwardhan, Vilas , Rigamonti, Cristina , Meer, Adriaan van der , Veer, Rozanne de, Zigmond, Ehud , Yehezkel, Eyal , Bruns, Tony , Große, Karsten , Wetten, Aaron , Jones, David , Dumortier, Jérôme , Pageaux, Georges‐Philippe , Lédinghen, Victor de , Chazouillères, Olivier , Groups, the Global & ERN Rare-Liver PBC Study, Osman, Karim T. , Bruns, Tony , Patwardhan, Vilas R , Lytvyak, Ellina , Corpechot, Christophe , Hansen, Bettina E. , Hirschfield, Gideon M. , Montaño‐Loza, Aldo J. , Parés, Albert , Schramm, Christoph , Dalekos, George Ν. , Gatselis, Nikolaos , Abbas, Nadir , Trivedi, Palak Jitendrakumar , Saffioti, Francesca , Barkai, László , Roccarina, Davide , Calvaruso, Vincenza , Fichera, Anna, Villamil, Alejandra , Medina‐Morales, Esli , Bonder, Alan , Carbone, Marco , Invernizzi, Pietro , Cristoferi, Laura , Kremer, Andreas E. , Deibel, Ansgar , Dyson, Jessica Katharine , Carrat, Fabrice , Groups, the Global & ERN Rare-Liver PBC Study, Russo, Francesco Paolo

Hepatology | September 21, 2023 | Volume: 79 | Issue: 1 | Pages: 39-48

10.1097/hep.0000000000000529 | PMID 37399238 Get It

Background and Aims: Normal alkaline phosphatase (ALP) levels in ursodeoxycholic acid (UDCA)-treated patients with primary biliary cholangitis (PBC) are associated with better long-term outcome. However, second-line therapies are currently recommended only when ALP levels remain above 1.5 times the upper limit of normal (×ULN) after 12-month UDCA. We assessed whether, in patients considered good responders to UDCA, normal ALP levels were associated with significant survival gains. Approach and Results: We performed a retrospective cohort study of 1047 patients with PBC who attained an adequate response to UDCA according to Paris-2 criteria. Time to liver-related complications, liver transplantation, or death was assessed using adjusted restricted mean survival time (RMST) analysis. The overall incidence rate of events was 17.0 (95% CI: 13.7–21.1) per 1000 out of 4763.2 patient-years. On the whole population, normal serum ALP values (but not normal gamma-glutamyl transpeptidase (GGT), alanine aminotransferase (ALT), or aspartate aminotransferase (AST); or total bilirubin < 0.6 ×ULN) were associated with a significant absolute complication-free survival gain at 10 years (mean 7.6 months, 95% CI: 2.7 - 12.6 mo.; p = 0.003). In subgroup analysis, this association was significant in patients with a liver stiffness measurement ≥ 10 kPa and/or age ≤ 62 years, with a 10-year absolute complication-free survival gain of 52.8 months (95% CI: 45.7–59.9, p < 0.001) when these 2 conditions were met. Conclusions: PBC patients with an adequate response to UDCA and persistent ALP elevation between 1.1 and 1.5 ×ULN, particularly those with advanced fibrosis and/or who are sufficiently young, remain at risk of poor outcome. Further therapeutic efforts should be considered for these patients.
Faculty Opinions recommendation of Long versus short peroral endoscopic myotomy for the treatment of achalasia: results of a non-inferiority randomised controlled trial.
Song, Louis M. Wong Kee

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 21, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.742616619.793600844 Get It

POEMS syndrome: Update on diagnosis, risk‐stratification, and management
Dispenzieri, Angela

American Journal of Hematology | September 21, 2023 | Volume: 98 | Issue: 12 | Pages: 1934-1950

10.1002/ajh.27081 | PMID 37732822 Get It

Abstract Disease Overview POEMS syndrome is a life‐threatening condition due to an underlying plasma cell neoplasm. The major criteria for the syndrome are polyradiculoneuropathy, clonal plasma cell disorder, sclerotic bone lesions, elevated vascular endothelial growth factor, and the presence of Castleman disease. Minor features include organomegaly, endocrinopathy, characteristic skin changes, papilledema, extravascular volume overload, and thrombocytosis. Diagnosis The diagnosis of POEMS syndrome is made with three of the major criteria, two of which must include polyradiculoneuropathy and clonal plasma cell disorder, and at least one of the minor criteria. Risk Stratification Because the pathogenesis of the syndrome is not well understood, risk stratification is limited to clinical phenotype rather than specific molecular markers. Risk factors include low serum albumin, age, pleural effusion, pulmonary hypertension, and reduced estimated glomerular filtration rate. Risk‐Adapted Therapy For those patients with a dominant plasmacytoma, first‐line therapy is irradiation. Patients with diffuse sclerotic lesions or disseminated bone marrow involvement should receive systemic therapy. Corticosteroids are temporizing, but alkylators and lenalidomide are the mainstays of treatment, the former either in the form of low‐dose conventional therapy or as high‐dose conditioning for stem cell transplantation. Thalidomide and bortezomib also have activity, but their benefit needs to be weighed against their risk of exacerbating the peripheral neuropathy. Daratumumab combinations also appear promising based on case series. Prompt recognition and institution of both supportive care measures and therapy directed against the plasma cell result in the best outcomes.
Opportunistic Screening With CT: Comparison of Phantomless BMD Calibration Methods
Bartenschlager, Stefan , Cavallaro, Alexander , Pogarell, Tobias, Chaudry, Oliver , Khosla, Sundeep , Schett, Georg , Khosla, Sundeep , Schett, Georg , Uder, Michael , Engelke, Klaus

Journal of Bone and Mineral Research | September 21, 2023 | Volume: 38 | Issue: 11 | Pages: 1689-1699

10.1002/jbmr.4917 | PMID 37732678 Get It

ABSTRACT Opportunistic screening is a new promising technique to identify individuals at high risk for osteoporotic fracture using computed tomography (CT) scans originally acquired for an clinical purpose unrelated to osteoporosis. In these CT scans, a calibration phantom traditionally required to convert measured CT values to bone mineral density (BMD) is missing. As an alternative, phantomless calibration has been developed. This study aimed to review the principles of four existing phantomless calibration methods and to compare their performance against the gold standard of simultaneous calibration (ΔBMD). All methods were applied to a dataset of 350 females scanned with a highly standardized CT protocol (DS1) and to a second dataset of 114 patients (38 female) from clinical routine covering a large range of CT acquisition and reconstruction parameters (DS2). Three of the phantomless calibration methods must be precalibrated with a reference dataset containing a calibration phantom. Sixty scans from DS1 and 57 from DS2 were randomly selected for this precalibration. For each phantomless calibration method first the best combination of internal reference materials (IMs) was selected. These were either air and blood or subcutaneous adipose tissue, blood, and cortical bone. In addition, for phantomless calibration a fifth method based on average calibration parameters derived from the reference dataset was applied. For DS1, ΔBMD results (mean ± standard deviation) for the phantomless calibration methods requiring a precalibration ranged from 0.1 ± 2.7 mg/cm3 to 2.4 ± 3.5 mg/cm3 with similar means but significantly higher standard deviations for DS2. Performance of the phantomless calibration method, which does not require a precalibration was worse (ΔBMD DS1: 12.6 ± 13.2 mg/cm3, DS2: 0.5 ± 8.8 mg/cm3). In conclusion, phantomless BMD calibration performs well if precalibrated with a reference dataset. © 2023 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
Machine Learning Algorithms Predict Long-Term Postoperative Opioid Misuse: A Systematic Review
Emam, Omar S. , Eldaly, Abdullah S. , Maita, Karla C. , Brown, Sally A., Haider, Clifton R. , Torres-Guzman, Ricardo A, Anne Brown, Sally, Ávila, Francisco R. , Torres‐Guzman, Ricardo A. , Garcia, John P. , Brown, Sally Anne, Forte, Antonio J.

The American Surgeon™ | September 21, 2023 | Volume: 90 | Issue: 1 | Pages: 140-151

10.1177/00031348231198112 | PMID 37732536 Get It

Introduction A steadily rising opioid pandemic has left the US suffering significant social, economic, and health crises. Machine learning (ML) domains have been utilized to predict prolonged postoperative opioid (PPO) use. This systematic review aims to compile all up-to-date studies addressing such algorithms’ use in clinical practice. Methods We searched PubMed/MEDLINE, EMBASE, CINAHL, and Web of Science using the keywords “machine learning,” “opioid,” and “prediction.” The results were limited to human studies with full-text availability in English. We included all peer-reviewed journal articles that addressed an ML model to predict PPO use by adult patients. Results Fifteen studies were included with a sample size ranging from 381 to 112898, primarily orthopedic-surgery-related. Most authors define a prolonged misuse of opioids if it extends beyond 90 days postoperatively. Input variables ranged from 9 to 23 and were primarily preoperative. Most studies developed and tested at least two algorithms and then enhanced the best-performing model for use retrospectively on electronic medical records. The best-performing models were decision-tree-based boosting algorithms in 5 studies with AUC ranging from .81 to .66 and Brier scores ranging from .073 to .13, followed second by logistic regression classifiers in 5 studies. The topmost contributing variable was preoperative opioid use, followed by depression and antidepressant use, age, and use of instrumentation. Conclusions ML algorithms have demonstrated promising potential as a decision-supportive tool in predicting prolonged opioid use in post-surgical patients. Further validation studies would allow for their confident incorporation into daily clinical practice.
Emphysematous Cystitis: A Rare Urologic Emergency
Riveros, Blanca Paola Pérez, Mohseni, Michael , Mohseni, Michael M

American Journal of Case Reports | September 21, 2023 | Volume: 24 | Issue: No issue available | Pages: No page available

10.12659/ajcr.941599 | PMID 37904334 Get It

Consensus recommendations for clinical assessment tools for the diagnosis of posterior cortical atrophy syndrome from the Atypical AD PIA of ISTAART
Pelak, Victoria S. , Tang‐Wai, David F. , Graff‐Radford, Jonathan , Rabinovici, Gil D. , Holden, Samantha K. , Townley, Ryan , Day, Gregory S. , Whitwell, Jennifer , Boon, Baayla D.C. , Putcha, Deepti , Onyike, Chiadi U. , Snyder, Heather M. , Yong, Keir , Yong, Keir X X , Day, Gregory S , Rabinovici, Gil D , Putcha, Deepti , Boeve, Bradley F. , Bouwman, Femke H. , Ossenkoppele, Rik , Crutch, Sebastian J.

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | September 21, 2023 | Volume: 15 | Issue: 3 | Pages: No page available

10.1002/dad2.12474 | PMID 39329067 Get It

AbstractINTRODUCTIONDelay in diagnosis of posterior cortical atrophy (PCA) syndrome is common, and the lack of familiarity with assessment tools for identifying visual cortical dysfunction is a contributing factor. We propose recommendations for the approach to the evaluation of PCA clinical features during the office visit, the neuropsychological evaluation, and the research setting. A recommended screening battery for eye clinics is also proposed.METHODSRecommendations were developed using results from a web‐based survey of members of Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART) Atypical Alzheimer's Disease Professional Interest Area (PIA), literature review, and consensus by the PCA assessment working party of the Atypical Alzheimer's Disease PIA.RESULTSSurvey results revealed robust agreement for assessment tool preferences for PCA features, and many respondents indicated that they reserve assessment tools for use only when PCA is suspected. For some PCA features, curated tools were preferred over validated battery tools, particularly for the office visit. Consensus recommendations superseded survey preferences for two core cognitive features within the 2017 PCA diagnostic criteria.DISCUSSIONThese consensus recommendations provide an evaluation framework for PCA clinical features and can facilitate timely and accurate recognition and diagnosis of PCA. Broader use of these tools should be sought, and development and validation of novel PCA clinical outcome assessments are needed to improve our understanding of atypical AD and other dementias and support the inclusion of those with PCA in treatment trials.